Loading
AK119 is an experimental monoclonal antibody from Akeso in phase 2 trials for colorectal cancer, aimed at CD73 / adenosine axis.
AK119 is a monoclonal antibody developed by Akeso. Its target is CD73 / adenosine axis (the sponsor names CD73). The sponsor states: AK119 is an anti-CD73 monoclonal antibody, studied in combination with AK112 for advanced solid tumours and colorectal cancer. ClinicalTrials.gov describes the intervention as: AK119 is an anti-CD73 monoclonal antibody. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in colorectal cancer. The largest, NCT05846867, plans to enrol 170 participants with primary completion was scheduled for 2026-05-08 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
AK119 is an anti-CD73 monoclonal antibody, studied in combination with AK112 for advanced solid tumours and colorectal cancer. Connects to CD73 / adenosine axis.
1.AK119 binds CD73 / adenosine axis.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AK119" OR ABSTRACT:"AK119") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AK119, not a curated reading list.
Shares Akeso, Colorectal cancer and the tag pipeline.
Shares Akeso and the tag pipeline.
Shares Akeso and the tag pipeline.
Shares Akeso and the tag pipeline.
Shares CD73 / adenosine axis and the tag pipeline.
Shares Akeso and the tag pipeline.
Shares Akeso and the tag pipeline.
Shares Akeso and the tag pipeline.